Notice of Annual General Meeting in Vicore Pharma Holding AB (publ)

2017-04-03 | Regulatory

Vicore Pharma Holding AB (publ), Reg. No. 556680-3804, hereby gives notice to shareholders to attend the Annual General Meeting on Wednesday 10 May 2017 at 3:00 p.m. at the office of the company,  c/o Astra Zeneca, Pepparedsleden 1, 431 83 Mölndal. Participating shareholders shall register in the reception at the main entrance of Astra Zeneca, at the address stated above, approximate 15 minutes before the meeting.

Notification of participation
Any shareholder wishing to participate at the Annual General Meeting (AGM) must be recorded as a shareholder in the share register maintained by Euroclear Sweden AB as of Thursday 4 May 2017, and must give notice of their intention to participate at the AGM to the company either by letter addressed to Vicore Pharma Holding AB, att. Nina Carlén, c/o Astra Zeneca, Pepparedsleden 1, 431 83 Mölndal, by telephone +46 (0) 31 78 80 560, or by e-mail to
nina.carlen@vicorepharma.com no later than 12:00 p.m. 5 May 2017. 

When notifying attendance, state your full name, personal identity number or corporate registration number, holding of shares, address, telephone number as well as the number of advisers (no more then 2). Notification shall, when applicable, be accompanied by proxy, certificate of registration and other documents regarding authorization.

Shares registered with a trustee
Shareholders whose shares are registered with a trustee must temporarily re-register their shares in their own name with Euroclear Sweden AB to be entitled to participate in the AGM. This means that shareholders should notify the trustee in ample time to allow registration in the share register by Wednesday 4 May 2017. 

Proxy
Shareholders who wish to be represented by proxy, must issue a dated power of attorney for the proxy. A format for the power of attorney can be obtained from the company and is also available on the company’s website, www.vicorepharma.com.  A certified copy of the current registration certificate or other appropriate documentation must be enclosed to an issued power of attorney by a legal entity. Power of attorney and registration certificate shall not be older than one year. The original power of attorney, and registration certificate when applicable, should be remitted by postal services in good time before the AGM to Vicore Pharma Holding AB.

Proposed agenda:

 0.       Opening of the Meeting.
1.       Election of chairman of the AGM.
2.       Election of keeper of the minutes of the AGM.
3.       Preparation and verification of the voting list.
4.       Election of two officers to verify the minutes.
5.       Determination of whether the AGM has been duly convened.
6.       Approval of the agenda.
7.       Presentation of the annual report and the auditors’ report submitted as well as the consolidated accounts and auditors´ report.
8.       Resolution on adoption of the income statement and balance sheet; and consolidated income statement and consolidated balance sheet.
9.       Resolution on appropriations of the company’s profit or loss as shown in the adopted balance sheet.
10.     Resolution on discharge from liability of the members of the board of directors and the CEO.
11.     Approval of the number of board of directors and deputy board of directors.
12.     Approval of the fees to be paid to the board members and auditors.
13.     Election of the board members and auditors.
14.     Resolution on authorization of the board of directors to issue new shares/convertibles/warrants.
15.     Resolution on authorization of the board of directors, or the party appointed by the Board, to make any minor adjustments to resolutions adopted by the AGM.
16.     Closing of the Meeting.

Decision proposals in summary:

Disposal of the profit (matter 9)
The board proposes that the AGM resolve to dispose the profit of the company in accordance with the board of directors proposal in the annual report. The board also proposes that no dividend for the financial year 2016 will be distributed.

Approval of the number of board of directors and deputy board of directors , approval of the fees to be paid to the board members and auditors and election of the board members (matter 11, 12 and 13)
Shareholders representing 38 percent of the shares and votes in the company proposes that the fees to be paid to the chairman of the board shall be SEK 250,000, to each board member not employed by the company SEK 75,000 and to the auditor on current account.

Shareholders representing 38 percent of the votes have proposed election of a new board of directors. The shareholders propose to the AGM that there be five board of directors and no deputies until the next annual general meeting, and also proposes that Kjell Stenberg, Peter Ström, Göran Wessman and Leif Darner be re-elected as board members, Göran Arvidsson is elected as new board member and Leif Darner be elected as new chairman of the board.

Göran Arvidsson is CEO of Hansa Medical since April 2015. Göran Arvidsson has important experience from the life science sector. He has been deputy CEO and CFO of the Swedish Orphan Biovitrum AB (publ), co-founder of Biovitrum and has been in managing positions with Pharmacia AB och Procordia AB.

For the period through the end of the next annual general meeting it is proposed that Ernst & Young AB, with authorized public accountant Stefan Kylebäck as the auditor-in-charge.

Authorization of the board of directors (matter 14)
The board proposes that the AGM authorize the board of directors to, on one or several occasions, until the next annual general meeting, resolve on issue of new shares and/or convertibles and/or warrants with payment in cash and/or in kind or by way of set-off or otherwise with conditions and thereby be able to derogate from shareholders pre-emptive right.

The aggregated number of shares that may be issued and the number of shares that may be subscribed for through converting promissory note, and the number of shares that may be subscribes for by right of option for subscribing new shares is limited to 4.000.000 shares.

The reason for the proposal is that the board deems it favorable for the company, in terms of expansion and raising capital, that the board of directors is allowed the capacity to resolve on issuing of shares without having to convene a general meeting.

The proposal from the board enables the board of directors to provide the company with, among other things, working capital, capital for acquisition of companies, acquisition of technical solutions and/or in order to reduce debt load.  

The reason for derogating from the general pre-emptive right (pro rata parte in relation to the existing ownership quota) is that such flexibility should facilitate raising capital in the company and that the possible distribution of ownership as a result of raising the capital deems favorable for the company and its current shareholders.

A share issue shall be on market terms based on the estimated market value of the company’s shares at the time of the share issue, subject to a possibility of a market term deduction of the subscription price at the option of the board of directors in case it is deemed necessary in order to execute the issue of new shares.  The board of directors is entitled to resolve on the detailed terms and conditions of the share issue. 

Number of shares and votes
On the notification date for the AGM, the total number of shares outstanding in the company is 14 368 504. The total number of votes is 14 368 504. The company does not hold any shares in itself.
On the extraordinary general meeting 27 March 2017 it was resolved to adopt new articles of association regarding the limits of the share capital and the highest and lowest amount of shares in the company and a directed issue of 1.500.000 shares. The issuing of shares has not been registered at the time for this notice but should be registered at the time of the AGM.

Disclosures
On the request of any shareholder and provided the board deems that it can be performed without any significant damage to the company, the board and the CEO will provide information on the circumstances that may impact the assessment of an agenda item and on conditions that might influence the assessment of the company's financial situation.

The resolutions made by the AGM in accordance with matter 14 are valid only if supported by at least 2/3 of the represented shares and votes.  

Complete proposals regarding matter 14 and 15 and all other statutory documents will be available to shareholders at company’s office and on the company’s website www.vicorepharma.se from 19 April 2017.

Gothenburg April 2017 

Vicore Pharma Holding AB (publ)

BOARD OF DIRECTORS

This is information which Vicore Pharma Holding AB is required to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided by the above contact person's auspices, for publication April 3, 2017 at. 09:00 CET. 

Vicorepharma

On vicorepharma.com, we use so-called cookies to analyze how our website is used in order to optimize and improve it. You choose yourself whether you want to consent to our use of cookies.

Vicorepharma is responsible for placing cookies on the website and for the processing of your personal data collected by them. For more information about our processing of your personal data, see our privacy policy

Cookie policy

Your consent applies to the following domain: vicorepharma.com
The cookie policy was last updated: 2023-01-24

Privacy Policy

Show the cookies used on our website

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Marketing cookies is used to track visitors on the website. The intention is to show ads that are relevant and engaging to the individual user and thus be more valuable to publishers and third-party advertisers.

  • AMP_TOKEN

    Purpose: Contains a token that can be used to retrieve a unique user ID.
    Issued by: AMP
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _fbp

    Purpose: Used to store and track visits across websites.
    Issued by: Facebook
    Lifespan: 3 months

    Domain: vicorepharma.com

  • _gac_

    Purpose: Used to store and track audience reach.
    Issued by: Google Ads
    Lifespan: 90 days

    Domain: vicorepharma.com

  • _lfa

    Purpose: Used to store and track audience reach.
    Issued by: Leadfeeder
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _lfa_test_cookie_stored

    Purpose: Used to test if _lfa was stored.
    Issued by: Leadfeeder
    Lifespan: 1 day

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _clck

    Purpose: Used to store a unique user ID.
    Issued by: Microsoft Clarity
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _clsk

    Purpose: Used to store and combine pageviews by a user into a single session recording.
    Issued by: Microsoft Clarity
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _hjAbsoluteSessionInProgress

    Purpose: Used to store unique visits.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjFirstSeen

    Purpose: Used to identify a new visitors’ first session.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

  • _hjid

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjIncludedInPageviewSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily pageview limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjIncludedInSessionSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily session limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjSessionUser{site_id}

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjSession{site_id}

    Purpose: A cookie that holds the current session data.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjTLDTest

    Purpose: Used to check if cookies can be loaded on the site and is removed shortly afterward.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

What are cookies?

A cookie is a small text file that is placed on your device (computer/mobile/tablet that has access to the internet) by the website you visit – if you give your consent to this. The cookie can, for example, recognize you as a user when you visit our website and make it possible to remember important information that makes your visit more comfortable and provides an improved user experience. Cookies are so-called passive files that cannot spread dangerous software or viruses on your mobile device or computer.

 

There are two types of cookies, permanent cookies and session cookies. At vicorepharma.com we use both permanent cookies and session cookies. Permanent cookies are saved as a file on the computer for a certain time until the server that placed them, or you as a visitor choose to delete them. Session cookies are temporarily stored when you as a visitor are on the website and disappear when you close your browser.

 

Cookies can also be divided into first-party cookies and third-party cookies. First-party cookies are placed by the website you are visiting, while third-party cookies are placed by another website. At vicorepharma.com, we use both first-party cookies and third-party cookies.

 

How to avoid cookies

When you visit our website, you can refuse all or certain types of cookies. You can also withdraw or change your consent at any time by clicking here.

 

You can also block cookies by changing the settings in your browser. Then your browser will automatically refuse cookies or inform you when a website requests to store cookies.

 

After your visit, you can review and delete the permanent cookies that have been stored in your browser. In the list below, you will see the name of the cookies vicorepharma.com saves so that you can easily identify them.

 

Here you will find more information about how to manage cookies in your browser:

 

Cookies used by third parties

On vicorepharma.com there may be content that is embedded from YouTube. YouTube places cookies in your browser when you visit youtube.com or when you click on embedded content from YouTube on our website. vicorepharma cannot control these cookies or the personal data and information that may be collected. vicorepharma does not use the targeted marketing services offered by YouTube. As a user, you therefore need to check YouTube’s website for further information on how they manage cookies, what information they collect and how you can delete any third-party cookies.

Necessary cookies is needed in order for the website's basic functions to work correctly and for us to be able to save your choice of cookies.

  • cookies_set

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

  • selected_cookies

    Purpose: Saves the visitor’s choice of cookies.
    Issued by: mk cookie master
    Lifespan: 1 year

    Domain: vicorepharma.com

Marketing cookies is used to track visitors on the website. The intention is to show ads that are relevant and engaging to the individual user and thus be more valuable to publishers and third-party advertisers.

  • AMP_TOKEN

    Purpose: Contains a token that can be used to retrieve a unique user ID.
    Issued by: AMP
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _fbp

    Purpose: Used to store and track visits across websites.
    Issued by: Facebook
    Lifespan: 3 months

    Domain: vicorepharma.com

  • _gac_

    Purpose: Used to store and track audience reach.
    Issued by: Google Ads
    Lifespan: 90 days

    Domain: vicorepharma.com

  • _lfa

    Purpose: Used to store and track audience reach.
    Issued by: Leadfeeder
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _lfa_test_cookie_stored

    Purpose: Used to test if _lfa was stored.
    Issued by: Leadfeeder
    Lifespan: 1 day

    Domain: vicorepharma.com

Statistical cookies helps the website owners to understand how visitors interact with the website by collecting and report this information.

  • _clck

    Purpose: Used to store a unique user ID.
    Issued by: Microsoft Clarity
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _clsk

    Purpose: Used to store and combine pageviews by a user into a single session recording.
    Issued by: Microsoft Clarity
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _ga

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 2 years

    Domain: vicorepharma.com

  • _gat

    Purpose: Used to throttle request rate. If Google Analytics is deployed via Google Tag Manager, this cookie will be named _dc_gtm_.
    Issued by: Google Analytics
    Lifespan: 1 minute

    Domain: vicorepharma.com

  • _gid

    Purpose: Used to understand how visitors’ navigate around the website.
    Issued by: Google Analytics
    Lifespan: 1 day

    Domain: vicorepharma.com

  • _hjAbsoluteSessionInProgress

    Purpose: Used to store unique visits.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjFirstSeen

    Purpose: Used to identify a new visitors’ first session.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

  • _hjid

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjIncludedInPageviewSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily pageview limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjIncludedInSessionSample

    Purpose: Used to check if the visitor is included in the data sample defined by the site’s daily session limit.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjSessionUser{site_id}

    Purpose: Used to store a unique user ID.
    Issued by: Hotjar
    Lifespan: 1 year

    Domain: vicorepharma.com

  • _hjSession{site_id}

    Purpose: A cookie that holds the current session data.
    Issued by: Hotjar
    Lifespan: 30 minutes

    Domain: vicorepharma.com

  • _hjTLDTest

    Purpose: Used to check if cookies can be loaded on the site and is removed shortly afterward.
    Issued by: Hotjar
    Lifespan: Session

    Domain: vicorepharma.com

General

Vicore Pharma Holding AB (“Vicore”) shall only process personal data in accordance with applicable data protection law and high industry standards.

 

Personal data.

Vicore processes personal data provided to us;
(i) by you in the day-to-day communications, or

(ii) in connection with entering into or performing an agreement or business arrangement with you, or
(iii) by a third party allowed by law or your consent.

The personal data may consist of contact and identification details and other information relevant to the situation.

 

Purpose.

Vicore process personal data for the purpose of communicating with you and to perform, manage and comply with agreements between us as well as rights and obligations which are allowed by law or applicable regulation.

 

Legal grounds.

The legal grounds for processing personal data is either;
(i) your consent which shall be considered provided when you either voluntary submit the personal data or enter into an agreement with us, or
(ii) a legitimate interest allowed under law.

 

Security

Vicore shall use adequate technical and organisational security measures to protect the personal data from loss and to safeguard against access from unauthorised persons.

Transfers of personal data may only occur;
(i) to third parties who perform services on Vicore behalf and who may only process personal data in accordance with our instructions, and may not use personal data for their own purposes; and
(ii) outside the EU/EEA only in accordance with applicable data protection laws and subject to the EU Commission’s standard contractual clauses, and
(iii) as otherwise permitted by law or your consent.

Duration.

The duration we process personal data is limited to what is reasonable for the purpose of the processing, unless otherwise required or permitted by law.

 

Rights

Vicore is the controller of the personal data processing, meaning that we are responsible for that the personal data is processed correctly and in accordance with applicable data protection laws.

Unless prevented by applicable law, regulation or agreement data subjects have the right to;
(i) know what personal data we process about them,
(ii) request that we rectify or erase inaccurate or incomplete personal data
(iii) object to specific processing of personal data, and
(iv) receive the personal data provided by them and have the personal data transferred to another party responsible for data processing.

All communications with Vicore regarding how we process personal data or exercise of any of your rights can be sent by e-mail to info@vicorepharma.com or by post to the address above.

Reports and complaints can also be directed to Datainspektionen who is the supervisory authority for our processing of personal data.